Advertisement

Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention

  • Anchit BhagatEmail author
  • Eugenie S. Kleinerman
Chapter
  • 88 Downloads
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1257)

Abstract

Doxorubicin is an anthracycline and one of the more effective chemotherapy agents used in the treatment of children, adolescents, and adults with osteosarcoma. Despite its effectiveness, cardiotoxicity is a major late effect that compromises the survival and quality of life of survivors of this and other cancers. Cardiotoxicity is the inability of the heart to pump blood through the body effectively. Doxorubicin-induced cardiotoxicity is dose dependent. Additionally, the age of the patients plays a role in susceptibility with younger patients having a greater risk for cardiotoxicity and heart failure years after treatment is complete. The exact mechanism(s) responsible for doxorubicin-induced cardiotoxicity is poorly understood, and further research needs to be done to elucidate the mechanisms. This chapter summarizes the identified mechanisms that may play a role in anthracycline-induced cardiotoxicity. We will also summarize the types of cardiomyopathies that have been described in survivors treated with doxorubicin and the current recommendations for monitoring survivor for the development of cardiomyopathies. Included will be the important search for defining early biomarkers to identify patients and survivors at risk. Finally, we will summarize some of the interventions proposed for decreasing anthracycline-induced cardiotoxicity.

Keywords

Cardiotoxicity Anthracycline Doxorubicin Dexrazoxane Osteosarcoma Chemotherapy Pediatric cancer Heart failure Cardiovascular disease 

References

  1. 1.
    Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB (2011) Anthracycline cardiotoxicity: from bench to bedside. NIH Public Access 26(22):3777–3784.  https://doi.org/10.1200/JCO.2007.14.9401.AnthracyclineCrossRefGoogle Scholar
  2. 2.
    McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM (2017) Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 31(1):63–75.  https://doi.org/10.1007/s10557-016-6711-0CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Yang F, Teves SS, Kemp CJ, Henikoff S (2014) Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta 1845(1):84–89PubMedGoogle Scholar
  4. 4.
    Chen SH, Chan N-L, Hsieh T (2013) New mechanistic and functional insights into DNA topoisomerases. Annu Rev Biochem 82(1):139–170.  https://doi.org/10.1146/annurev-biochem-061809-100002CrossRefPubMedGoogle Scholar
  5. 5.
    Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70(1):369–413CrossRefGoogle Scholar
  6. 6.
    Vejpongsa P, Yeh ETH (2014) Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther 95(1):45–52.  https://doi.org/10.1038/clpt.2013.201CrossRefPubMedGoogle Scholar
  7. 7.
    Liu B, Li H, Qu H, Sun B (2006) Nitric oxide synthase expressions in ADR-induced cardiomyopathy in rats. BMB Rep 39(6):759–765.  https://doi.org/10.5483/bmbrep.2006.39.6.759CrossRefGoogle Scholar
  8. 8.
    Lobo V, Patil A, Phatak A, Chandra N (2010) Free radicals, antioxidants and functional foods: impact on human health. Pharmacogn Rev 4(8):118.  https://doi.org/10.4103/0973-7847.70902CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Pham-Huy LA, He H, Pham-Huy C (2008) Free radicals, antioxidants in disease and health. Int J Biomed Sci 4(2):89–96PubMedPubMedCentralGoogle Scholar
  10. 10.
    Seifried HE, Anderson DE, Sorkin BC, Costello RB (2004) Free radicals: the pros and cons of antioxidants. Executive summary report. J Nutr 134(11):3143S–3163S.  https://doi.org/10.1093/jn/134.11.3143SCrossRefPubMedGoogle Scholar
  11. 11.
    Vejpongsa P, Yeh ETH (2014) Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 64(9):938–945.  https://doi.org/10.1016/j.jacc.2014.06.1167CrossRefPubMedGoogle Scholar
  12. 12.
    Cappetta D, Urbanek K, Rossi F, De Angelis A (2018) Anthracycline cardiotoxicity: new actors on the stage. Transl Cancer Res 7(S5):S580–S583.  https://doi.org/10.21037/tcr.2018.04.24CrossRefGoogle Scholar
  13. 13.
    Said R, Nickolich M, Lenihan DJ, Tsimberidou AM (2017) Cardiotoxicity of anticancer therapies. Cardio-Oncology: Clin Overlap Cancer Heart Dis 5(February):15–42.  https://doi.org/10.1007/978-3-319-43096-6_2CrossRefGoogle Scholar
  14. 14.
    Shaikh AY, Shih JA (2012) Chemotherapy-induced cardiotoxicity. Curr Heart Fail Rep 9(2):117–127.  https://doi.org/10.1007/s11897-012-0083-yCrossRefPubMedGoogle Scholar
  15. 15.
    Bloom MW, Greenberg B, Jaarsma T, Januzzi JL, Lam CSP, Maggioni AP et al (2017) Heart failure with reduced ejection fraction. Nat Rev Dis Primers 3:1–20.  https://doi.org/10.1038/nrdp.2017.58CrossRefGoogle Scholar
  16. 16.
    Tan TC, Scherrer-Crosbie M (2012) Assessing the cardiac toxicity of chemotherapeutic agents: role of echocardiography. Curr Cardiovasc Imaging Rep 5(6):403–409.  https://doi.org/10.1007/s12410-012-9163-3CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Tan LL, Lyon AR (2018) Role of biomarkers in prediction of cardiotoxicity during cancer treatment. Curr Treat Options Cardiovasc Med 20(7).  https://doi.org/10.1007/s11936-018-0641-z
  18. 18.
    Nicol M, Baudet M, Cohen-solal A (2019) Co-morbidities subclinical left ventricular dysfunction during chemotherapy co-morbidities. Cardiac Failure Review 942:31–36CrossRefGoogle Scholar
  19. 19.
    Moazeni S, Cadeiras M, Yang EH, Deng MC, Nguyen K-L (2017) Anthracycline induced cardiotoxicity: biomarkers and “Omics” technology in the era of patient specific care. Clin Transl Med 6(1).  https://doi.org/10.1186/s40169-017-0148-3
  20. 20.
    Santos DS, Goldenberg RCS (2018) Doxorubicin-induced cardiotoxicity: from mechanisms to development of efficient therapy (Chapter 1). Cardiotoxicity: Intech Open, pp 3–24Google Scholar
  21. 21.
    Renu K, Abilash VG, Tirupathi Pichiah PB, Arunachalam S (2018) Molecular mechanism of doxorubicin-induced cardiomyopathy – an update. Eur J Pharmacol 818(October 2017):241–253.  https://doi.org/10.1016/j.ejphar.2017.10.043CrossRefPubMedGoogle Scholar
  22. 22.
    Volkova M, Russell R (2012) Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 7(4):214–220.  https://doi.org/10.2174/157340311799960645CrossRefGoogle Scholar
  23. 23.
    Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV et al (2014) Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Investig 124(2):617–630.  https://doi.org/10.1172/JCI72931CrossRefPubMedGoogle Scholar
  24. 24.
    Minotti G, Salvatorelli E, Menna P, Ronchi R, Cairo G (2001) Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 61(23):8422–8428PubMedGoogle Scholar
  25. 25.
    Nebigil CG, Désaubry L (2018) Updates in anthracycline-mediated cardiotoxicity. Front Pharmacol 9(NOV):1–13.  https://doi.org/10.3389/fphar.2018.01262CrossRefGoogle Scholar
  26. 26.
    Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL (2012) Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52(6):1213–1225.  https://doi.org/10.1016/j.yjmcc.2012.03.006CrossRefPubMedGoogle Scholar
  27. 27.
    Alkuraishy HM, Al-gareeb AI, Al-hussaniy HA (2017) Doxorubicin-induced cardiotoxicity: molecular mechanism and protection by conventional drugs and natural products. Int J Clin Oncol Cancer Res 2(2):31–44.  https://doi.org/10.11648/j.ijcocr.20170202.12CrossRefGoogle Scholar
  28. 28.
    Licata S, Saponiero A, Mordente A, Minotti G (2000) Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Chem Res Toxicol 13(5):414–420.  https://doi.org/10.1021/tx000013qCrossRefPubMedGoogle Scholar
  29. 29.
    Mitry MA, Edwards JG (2016) Doxorubicin induced heart failure: phenotype and molecular mechanisms. IJC Heart Vasc 10:17–24.  https://doi.org/10.1016/j.ijcha.2015.11.004CrossRefGoogle Scholar
  30. 30.
    Pecoraro M, Del Pizzo M, Marzocco S, Sorrentino R, Ciccarelli M, Iaccarino G et al (2016) Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity. Toxicol Appl Pharmacol 293:44–52.  https://doi.org/10.1016/j.taap.2016.01.006CrossRefPubMedGoogle Scholar
  31. 31.
    Langer SW (2014) Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Manag Res 6:357–363.  https://doi.org/10.2147/CMAR.S47238CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Ganatra S, Nohria A, Shah S, Groarke JD, Sharma A, Venesy D et al (2019) Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardio-Oncology 5(1):1–12.  https://doi.org/10.1186/s40959-019-0036-7CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Wang F, Iskra B, Kleinerman E, Alvarez-florez C, Andrews T, Shaw A et al (2018) Aerobic exercise during early murine doxorubicin exposure mitigates cardiac toxicity. J Pediatr Hematol Oncol 40(3):208–215CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of PediatricsMD Anderson Cancer CenterHoustonUSA

Personalised recommendations